Blockchain Registration Transaction Record

Tonix Pharma's TONMYA Study Shows Faster Absorption for Fibromyalgia Treatment

Tonix Pharmaceuticals publishes study showing TONMYA's faster absorption for fibromyalgia treatment. First new fibromyalgia drug in 15 years with potential for improved sleep and pain management.

This development matters because fibromyalgia affects millions worldwide, often causing chronic pain, fatigue, and sleep disturbances that significantly impair quality of life. The condition has seen limited treatment advances in recent years, leaving many patients with inadequate options. TONMYA's sublingual formulation offering faster absorption and improved bioavailability could provide more effective symptom management, particularly for nonrestorative sleep—a core fibromyalgia complaint. Beyond immediate patient benefits, Tonix's broader pipeline targeting CNS disorders and immunological conditions addresses multiple areas of high unmet medical need. The company's research into TONMYA for depression and stress disorders, along with programs for rare diseases like Prader-Willi syndrome and transplant rejection prevention, demonstrates a comprehensive approach to challenging medical conditions. For investors and the healthcare community, Tonix represents innovation in biotechnology with potential market impact across several therapeutic areas.